AcoArt II-BTK试验长期结果:药物涂层球囊血管成形术与普通球囊治疗膝下动脉病变的比较
AcoArt II-BTK是一项前瞻性、多中心、随机、单盲试验,纳入120例重症肢体缺血患者,1:1随机接受药物涂层球囊(DCB)血管成形术或经皮腔内血管成形术(PTA)。5年随访显示,DCB组全因死亡免除率高于PTA组(74.6% vs 57.2%,log-rank p=0.04),复合主要不良事件发生率低于PTA组(34.5% vs 56.1%,log-rank p=0.013)。
要点
- DCB组5年全因死亡免除率74.6%,高于PTA组的57.2%(log-rank p=0.04)。
- DCB组复合主要不良事件发生率34.5%,低于PTA组的56.1%(log-rank p=0.013)。
- 大截肢率DCB组5.2% vs PTA组1.8%(log-rank p=0.347),临床驱动靶病变血运重建免除率70.5% vs 53.7%(log-rank p=0.058)。
核心结论
- 对重症肢体缺血患者行膝下动脉血运重建,使用Litos/Tulip DCB血管成形术的5年总生存优于PTA。
- DCB血管成形术组在5年随访期间复合主要不良事件发生率持续低于PTA组。
研究设计与样本
- AcoArt II-BTK试验为前瞻性、多中心、随机、单盲试验,纳入120例重症肢体缺血患者。
- 患者按1:1随机分配至DCB血管成形术组或PTA组。
- 5年评估包括全因死亡免除、临床驱动靶病变血运重建免除和大截肢发生,以及复合主要不良事件发生率。
主要发现
- 5年全因死亡免除率DCB组为74.6%(Kaplan-Meier估计),PTA组为57.2%(log-rank p=0.04)。
- 大截肢率DCB组为5.2%,PTA组为1.8%(log-rank p=0.347)。
- 临床驱动靶病变血运重建免除率DCB组为70.5%,PTA组为53.7%(log-rank p=0.058)。
- 复合主要不良事件发生率DCB组为34.5%,PTA组为56.1%(log-rank p=0.013),该统计学显著差异持续贯穿5年随访期。
临床怎么用
- 作者指出,这些阳性发现为使用DCB治疗膝下动脉疾病提供了有力证据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Previous studies have indicated mixed short-term outcomes between drug-coated balloon (DCB) angioplasty and percutaneous transluminal angioplasty (PTA) in the treatment of infrapopliteal lesions. However, the long-term durability of DCB angioplasty remains uncertain. The objective of this study is to present the long-term outcomes of DCB angioplasty for infrapopliteal lesions in patients with critical limb ischemia (CLI). MATERIALS AND METHODS: The AcoArt II-BTK Trial was a prospective, multicenter, randomized, single-blinded trial that enrolled 120 patients with CLI. The patients were randomized 1:1 to DCB angioplasty or PTA. Assessments over 5 years included freedom from all-cause death, freedom from clinically driven target lesion revascularization, and occurrence of major amputation. Additional endpoints included the rate of composite major adverse events. RESULTS: Over 5 years, patients treated with DCB angioplasty demonstrated a higher rate of freedom from all-cause death than patients treated with PTA (Kaplan-Meier estimate 74.6% vs 57.2%; log-rank p=0.04). The major amputation rate was 5.2% for DCB angioplasty compared with 1.8% for PTA (log-rank p=0.347). Freedom from clinically driven target lesion revascularization was 70.5% and 53.7%, respectively (log-rank p=0.058). The rate of composite major adverse events was 34.5% for DCB angioplasty and 56.1% for PTA (log-rank p=0.013), and this statistically significant difference persisted throughout the 5-year follow-up period. CONCLUSION: Infrapopliteal artery revascularization in patients with CLI using Litos/Tulip DCB angioplasty showed superior 5-year overall survival compared with PTA. The DCB angioplasty group had a consistently lower rate of major adverse events within 5 years of follow-up.Clinical ImpactThe use of DCB in infrapopliteal arterial lesions has been controversial regarding both early and mid-term outcomes, with limited data on long-term results. However, this article demonstrates that the Litos/Tulip DCB exhibits favorable long-term outcomes in infrapopliteal artery lesions. These positive findings provide robust evidence supporting the use of DCB in treating infrapopliteal artery disease.
引用
- Sun G, Liu J, Jia X, et al. Long-term Outcomes of the AcoArt II-BTK Trial: Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons for the Treatment of Infrapopliteal Artery Lesions. J Endovasc Ther. 2024. PMID: 39692034. doi:10.1177/15266028241304303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。